Navigation Links
First prospective trial shows molecular profiling timely for tailoring therapy
Date:5/15/2013

ns to provide an accurate statistical analysis of response to novel drugs, says Giaccone.

Giaccone led the clinical trial while at the National Cancer Institute where he was the Chief of the Medical Oncology Branch, before he joined Georgetown in January. Researchers at Oregon Health & Science University also participated.

CUSTOM enrolled patients diagnosed with advanced stage non-small cell lung cancer, small cell lung cancer or thymic cancer. Researchers used next-generation sequencing, which was novel at the time, to look at almost 200 genes. From this, patients were assigned to different treatment groups based on genetic mutations or amplification.

Results from the largest group patients with non-small cell lung cancer had either an EGFR or a KRAS mutation, and results showed that those with EGFR mutations had a very high response to the drug erlotinib. "This is nothing new; we essentially confirmed what was already known," Giaccone says. But they also discovered that patients with KRAS mutations did not benefit from the single agent investigational drug selumetinib, which is being studied for use in a number of cancers, including non-small cell lung cancer.

Results for the patients with small cell lung or thymic cancers were inconclusive, primarily because the investigated mutations were rare not enough patients had specific mutations to adequately test response to therapy. "When we started the study, we didn't know how frequently the mutations occurred," Giaccone says. "Now we know that many mutations represent only 1 to 2 percent of patients and to do this right, you need to screen thousands of patients. That is only possible with a global study that involves, potentially, hundreds of institutions.

"The CUSTOM trial demonstrates both the feasibility of the approach for common mutations that it is possible to have a real-time genetic analysis that guides treatment as well as the difficulty of studying treatment for
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. First contact: Early intervention key in diagnosis and treatment of serious mental illness
3. Donor Kidney Re-Used in Second Patient After Failing in First
4. Many Who First Misuse Prescription Pills Get Them From Friends, Family: Report
5. First-of-its-kind Menopause Map helps women navigate treatment
6. First recipients of AcademyHealths Presidential Scholarship announced
7. Kessler Foundation researchers present at first International Congress on Cognition in MS
8. Whos the Dad? First-Trimester Blood Test May Tell
9. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
10. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
11. First study investigating possible link between sunscreen ingredient and endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 “ LiveSchool ” was featured ... takes a look at the latest and coolest applications ... Toohey, the host of AppWatch and technology expert, conducted ... application allows teachers to reward students with good behavior. ... especially in the classroom. And the good people ...
(Date:5/4/2015)... Jacksonville, Fla. (PRWEB) May 04, 2015 ... American Heart Association/American Stroke Association’s Get With The ... the Target: Stroke Honor Roll. The award recognizes ... stroke patients receive the most appropriate treatment according ... latest scientific evidence. , To receive the Gold ...
(Date:5/4/2015)... Ticket Down is a reputable source for ... . While the World Cup is the most known ... years, the International Champions Cup is one of the biggest ... attendance record for soccer in the United States set when ... the University of Michigan. This year, the defending champion Manchester ...
(Date:5/4/2015)... Ticket Down is a reputable source for authentic Paul ... South Carolina. Fans of Paul McCartney have to be ... originally kicked off in 2013. The most visited continent of ... performer recently announced that he would be adding additional dates ... in Charlottesville, VA at John Paul Jones Arena on ...
(Date:5/4/2015)... NY (PRWEB) May 04, 2015 Sheltering ... Learning Center from Hale House. The Mother Hale Learning ... high-quality, affordable Early Childhood Education. Sheltering Arms will begin ... continue to be served by the center. , Opened ... children ages six weeks to five years, many of ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2
... , TUESDAY, Nov. 16 (HealthDay News) -- Antibiotics may help ... drugs also come with the risk of side effects, concludes ... and 10 percent of children experience side effects, such as ... "If you have 100 healthy children with an ...
... advanced liver cancer with the agent doxorubicin (routinely used ... sorafenib resulted in greater overall survival and progression-free survival, ... according to a study in the November 17 issue ... is the sixth most common malignancy worldwide, with approximately ...
... Mich. Transforming vacant urban lots into farms and ... of their fruits and vegetables. As city officials ... study indicates that a combination of urban farms, community ... to extend the growing season could supply local ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... open clogged arteries in addition to standard drug therapy ... in diabetics with heart disease, new research finds. ... Association,s annual meeting in Chicago, is part of a ...
... Nov. 16 (HealthDay News) -- Implantable cardioverter defibrillators (ICDs) that ... for necessary upgrades -- can be safely used again for ... on a small study of 31 patients in India who ... from other patients. The study, led by Dr. Behzad ...
... Researchers have found that many cystic fibrosis (CF) patients in Canada ... , which can increase the risk of death or the need ... strain, first identified in the U.K., is yet common among ... CF patients in Ontario and found that 102 of them were ...
Cached Medicine News:Health News:Antibiotics a Mixed Bag for Kids' Ear Infections: Analysis 2Health News:Antibiotics a Mixed Bag for Kids' Ear Infections: Analysis 3Health News:Combination therapy improves survival time for patients with advanced liver cancer 2Health News:Detroit's urban farms could provide a majority of produce for local residents 2Health News:Adding Surgery to Meds May Help Diabetics With Heart Disease 2Health News:Old Defibrillators Safe for Re-use 2Health News:Severe Bacterial Strain Found in Cystic Fibrosis Patients in Canada 2
(Date:5/4/2015)... TAIPEI , May 4, 2015 ... partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... BAX ) jointly announced that Baxter has ... European Medicines Agency (EMA) for MM-398 (irinotecan liposome ... metastatic adenocarcinoma of the pancreas who have been ...
(Date:5/4/2015)... DOYLESTOWN, Pa. , May 4, 2015  Makindus, ... announced today that the European Medicines Agency (EMA) has ... for the treatment of Stargardt,s Disease. "We ... for MI-100 to treat Stargardt,s disease in place for ... our development program in the United States ...
(Date:5/4/2015)... Bayer HealthCare (Bayer) has entered into an ... ISIS ) on ISIS-FXI Rx, an antisense investigational ... Under the agreement Bayer will further develop and commercialize ... need. As part of the clinical development program, Bayer ... in an appropriate patient community. "Bayer ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... Delcath Systems, Inc. (Nasdaq: DCTH ) announced ... discuss its recent corporate developments and update its progress on ... President and Chief Executive Officer will host the call. ... 800-322-5044 for domestic participants and 617-614-4927 for international participants, both ...
... 2011 CVS Caremark Corporation (NYSE: CVS ... present at two investor conferences in the month of ... CVS Caremark, will be making a presentation to investors ... on Thursday, November 10th, at approximately 10:00 a.m. MST ...
Cached Medicine Technology:Delcath Systems to Report Third Quarter Progress and Conduct Conference Call 2Delcath Systems to Report Third Quarter Progress and Conduct Conference Call 3CVS Caremark to Present at Upcoming Conferences 2
... proven electrophoretic transfer apparatus incorporating state-of-the-art plate ... Its design allows for a very close ... with a low voltage power source such ... field in volts/cm. The result is exceptionally ...
... RNA from agarose gels to hybridization membranes ... speed and efficiency of transfer by allowing ... ,Part of an integrated system allowing electrophoresis, ... 2.5 hours, versus 29 hours required for ...
... Transfers depurinated DNA and RNA from agarose ... as 15 minutes ,Increases speed and efficiency ... be applied to gel ,Part of an ... and UV crosslinking in 2.5 hours, versus ...
Ice block will provide sufficient cooling for most normal blotting applications. Sealed block is held submerged in transfer buffer. Ice block will not spill during refreezing....
Medicine Products: